PT  - JOURNAL ARTICLE
AU  - Engjom, Hilde Marie
AU  - Ramakrishnan, Rema
AU  - Vousden, Nicola
AU  - Bunch, Kathryn
AU  - Morris, Edward
AU  - Simpson, Nigel
AU  - Gale, Chris
AU  - O’Brien, Pat
AU  - Quigley, Maria
AU  - Brocklehurst, Peter
AU  - Kurinczuk, Jennifer J
AU  - Knight, Marian
TI  - Severity of maternal SARS-CoV-2 infection and perinatal outcomes during the Omicron variant dominant period: UK Obstetric Surveillance System national cohort study
AID  - 10.1101/2022.03.07.22271699
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.03.07.22271699
4099  - http://medrxiv.org/content/early/2022/03/09/2022.03.07.22271699.short
4100  - http://medrxiv.org/content/early/2022/03/09/2022.03.07.22271699.full
AB  - Objectives To describe the severity of maternal infection when the Omicron SARS-CoV-2 variant was dominant (15/12/21-14/01/22) and compare outcomes among groups with different vaccination status.Design Prospective cohort studySetting UK consultant-led maternity unitsParticipants Pregnant women hospitalised with a positive SARS-CoV-2 PCR test up to 7 days prior to admission and/or during admission up to 2 days after giving birth.Main outcome measures Symptomatic or asymptomatic infection. Vaccination status. Severity of maternal infection (moderate or severe infection according to modified WHO criteria). Mode of birth and perinatal outcomes.Results Out of 1561 women admitted to hospital with SARS-CoV-2 infection, 449 (28.8%) were symptomatic. Among symptomatic women admitted, 86 (19.2%) had moderate to severe infection; 51 (11.4%) had pneumonia on imaging, 62 (14.3%) received respiratory support, and 19 (4.2%) were admitted to the intensive care unit (ICU). Three women died (0.7%). Vaccination status was known for 383 symptomatic women (85.3%) women; 249 (65.0%) were unvaccinated, 45 (11.7%) had received one vaccine dose, 76 (19.8%) had received two doses and 13 (3.4%) had received three doses. 59/249 (23.7%) unvaccinated women had moderate to severe infection, compared to 10/45 (22.2%) who had one dose, 9/76 (11.8%) who had two doses and 0/13 (0%) who had three doses. Among the 19 symptomatic women admitted to ICU, 14 (73.7%) were unvaccinated, 3 (15.8%) had received one dose, 1 (5.3%) had received two doses, 0 (0%) had received 3 doses and 1 (5.3%) had unknown vaccination status.Conclusion The risk of severe respiratory disease amongst unvaccinated pregnant women admitted with symptomatic SARS-CoV-2 infection during the Omicron dominance period was comparable to that observed during the period the wildtype variant was dominant. Most women with severe disease were unvaccinated. Vaccine coverage among pregnant women admitted with SARS-CoV-2 was low compared to the overall pregnancy population and very low compared to the general population. Ongoing action to prioritise and advocate for vaccine uptake in pregnancy is essential.SUMMARY BOXWhat is already known on this topicIn non-pregnant adults, growing evidence indicates a lower risk of severe respiratory disease with the Omicron SARS-CoV-2 Variant of Concern (VOC).Pregnant women admitted during the periods in which the Alpha and Delta VOC were dominant were at increased risk of moderate to severe SARS-CoV-2 infection compared to the period when the original wildtype infection was dominant.Most women admitted to hospital with symptomatic SARS-CoV-2 infection have been unvaccinated.What this study addsOne in four women who had received no vaccine or a single dose had moderate to severe infection, compared with one in eight women who had received two doses and no women who had received three dosesThe proportional rate of moderate to severe infection in unvaccinated pregnant women during the Omicron dominance period is similar to the rate observed during the wildtype dominance periodOne in eight symptomatic admitted pregnant women needed respiratory support during the period when Omicron was dominantCompeting Interest StatementAll authors have completed the ICMJE uniform disclosure form www.icmje.org/coi_disclosure.pdf and declare: MK, MQ, PB, POB, JJK received grants from the NIHR in relation to the submitted work. HE participated in this work as academic visitor to the NPEU with funding from The Norwegian Research Council, grant no 320181, and travel grant from the Nordic Federation of Societies of Obstetrics and Gynecology Research fund, grant no 6302. KB, NV, RR, NS, CG have no conflicts of interest to declare. EM is Trustee and President of RCOG, Trustee of British Menopause Society and Chair of the Board of Trustees Group B Strep Support. POB is Vice President of RCOG and Co-Chair of the RCOG Vaccine Committee. No other relationships or activities that could appear to have influenced the submitted work.”Clinical Protocols https://www.npeu.ox.ac.uk/ukoss/current-surveillance/covid-19-in-pregnancy. Funding StatementThe study was funded by the National Institute for Health Research HS&DR Programme (project number 11/46/12). MK is an NIHR Senior Investigator. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The HRA NRES Committee East Midlands Nottingham 1 gave ethical approval for this work (Reference Number 12/EM/0365). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData Sharing Data cannot be shared publicly because of confidentiality issues and potential identifiability of sensitive data as identified within the Research Ethics Committee application/approval. Requests to access the data can be made by contacting the National Perinatal Epidemiology Unit data access committee via general@npeu.ox.ac.uk.